| Room | Room 1 | Room 2 | Room 3 | Room 4 |
|---|---|---|---|---|
| Date | Thursday, March 31, 2022 | |||
| 08:00-09:00 | Registration | |||
| 08:50-09:00 | Opening Remark | |||
| 9:00-10:30 | [JS01] KAI-KSH Joint Session | [SS01] Pediatric disease | [SS02] Lymphoma (1) - B cell / CLL | [ES01] Platelet Disorder |
| Next generation CAR-T cell therapy against hematological malignancies Kyungho Choi, Korea |
Primary immune regulatory disorder for the pediatric hematologist and oncologist Shanmuganathan Chandrakasan, USA |
Molecular classification of diffuse large B-cell lymphoma and novel treatment strategies Daisuke Ennishi, Japan |
Diagnostic work up of inherited platelet disorder Bohyun Kim, Korea |
|
| Effective conditioning regimen in adoptive T cell therapy of cancer Chungyong Han, Korea |
Clonal evolution and somatic reversion in bone marrow failure Akiko Shimamura, USA |
Novel immunotherapeutic antibodies for B-cell NHL Gilles Salles, USA |
Recent advances in treatments of immune thrombocytopenia Daesik Kim, Korea |
|
| Tissue resident memory T cells in multiple myeloma Yoon Seok Choi, Korea |
Molecular landscape of pediatric AML Soheil Meshinchi, USA |
Targeting B-cell receptor and BCL-2 in chronic lymphocytic leukemia Susan M. O'Brien, USA |
Thrombocytopenia in pregnancy Young Hoon Park, Korea |
|
| T-cell-based immunotherapeutic strategies against EBV-positive malignancies using the novel TCR specific for LMP1 antigen Tai-Gyu Kim, Korea |
||||
| 10:30-11:15 | Plenary Lecture I | |||
| Immune landscape of hematological malignancies and functional screening tools Satu Mustjoki, Finland |
||||
| 11:15-11:30 | Break | |||
| 11:30-12:10 | [SY01] Handok
Sponsored by
|
[SY02] Astellas
Sponsored by
|
[SY03] Novartis
Sponsored by
|
[SY04] Janssen
Sponsored by
|
| What is the role of C5 inhibitors in PNH? Jin Seok Kim, Korea |
Gilteritinib: ADMIRAL study and real world experience Byung Sik Cho, Korea |
Role of CD19-directed CAR-T therapy in patients with DLBCL (Novartis Kymriah symposium) Koji Izutsu, Japan |
Immunotherapy in multiple myeloma Ajai Chari, USA |
|
| 12:10-12:40 | E-poster Exhibition | |||
| 12:40-13:40 | Young Investigator Presentation | [OP01] AML, MDS | [OP02] Lymphoma, Histiocytosis | [OP03] Laboratory Hematology |
| 13:40-13:55 | Break | |||
| 13:55-15:25 | [AS01] Asian Session 1 - AA (13:55-14:55) |
[SS03] MPN | [SS04] MM | [ES02] AML |
| Korean treatment guideline for aplastic anemia Jun Ho Jang, Korea |
Recent advances in molecular diagnosis, prognosis and monitoring of MPNs Myungshin Kim, Korea |
Evolution of myeloma from the normal plasma cell to disease complexity Niccolo Bolli, Italy |
Human AML stem cell: evolution of concept Dong Yeop Shin, Korea |
|
| Aplastic anemia immunosuppressive therapy in China Zhao Xin, China |
Molecular mechanisms underlying the development of MPN by mutant calreticulin and the therapeutic potential of an antibody targeting mutant calreticulin Norio Komatsu, Japan |
The power of ONE: immunology in the age of single cell genomics Ido Amit, Israel |
Recent update of AML risk stratification Hyoeun Shim, Korea |
|
| Clinical significance of detecting HLA-class I allele-lacking leukocytes in patients with aplastic anemia Kohei Hosokawa, Japan |
Targeting proinfl ammatory signaling, including IL8, in myelofi brosis: the pathway into the clinic Andrew J. Dunbar, USA |
Clinical implication of immune network in multiple myeloma Je-Jung Lee, Korea |
FLT3 mutated AML Jae-Sook Ahn, Korea |
|
| 15:25~15:40 | Break | |||
| 15:40~17:10 | [JS02] KOGO-KSH Joint Session | [SS05] CML | [SS06] Cell Therapy / Transplantation | [ES03] Thrombosis / Hemostasis |
| Developing single-cell data integration pipeline to find novel cell types and gene markers for immune diseases Jong-Eun Park, Korea |
Resistance mechanism in CML Kimmo Porkka, Finland |
Immune landscapes and chemotherapy resistance in AML Sergio Rutella, UK |
Advances in laboratory assessment in thrombosis/hemostasis JaeWoo Song, Korea |
|
| Detection of enhancer hijacking of oncogenes in multiple myeloma Jin-Wu Nam, Korea |
Mutational landscape in CML Simona Soverini, Italy |
Towards next-generation T cell engineering for cancer Chan Hyuk Kim, Korea |
Cancer-associated thrombosis Ho-Young Yhim, Korea |
|
| Pharmacogenetics of childhood acute lymphoblastic leukemia Hyery Kim, Korea |
CML/MPN stem cells and the bone marrow microenvironment Steffen Koschmieder, Germany |
Endogenous retroviruses as a source of tumor antigens in solid tumors and acute myeloid leukemia Stéphane Depil, France |
Recent advances in the management of immune mediated TTP Sung Hwa Bae, Korea |
|
| Evaluating leukemic structural variations using optical genome mapping Saeam Shin, Korea |
||||
